Biotechnology Assets, S.A. (BME:BST)
Spain
· Delayed Price · Currency is EUR 0.279
-0.002 (-0.71%)
At close: Dec 5, 2025
Biotechnology Assets Revenue
Biotechnology Assets had revenue of 1.19M EUR in the half year ending June 30, 2025, a decrease of -27.25%. This brings the company's revenue in the last twelve months to 3.05M, down -9.48% year-over-year. In the year 2024, Biotechnology Assets had annual revenue of 2.97M, down -24.13%.
Revenue (ttm)
3.05M
Revenue Growth
-9.48%
P/S Ratio
6.40
Revenue / Employee
101.77K
Employees
34
Market Cap
19.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.97M | -943.29K | -24.13% |
| Dec 31, 2023 | 3.91M | 950.58K | 32.14% |
| Dec 31, 2022 | 2.96M | -324.07K | -9.87% |
| Dec 31, 2021 | 3.28M | 390.31K | 13.50% |
| Dec 31, 2020 | 2.89M | -345.59K | -10.68% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.52B |
| Laboratorios Farmaceuticos Rovi | 724.20M |
| Almirall | 1.09B |
| Faes Farma | 571.12M |
| Pharma Mar | 179.28M |
| Clínica Baviera | 296.76M |
| Oryzon Genomics | 7.36M |
| Prim, S.A. | 240.68M |